Testimonial by Fernanda Waechter!

Fernanda Waechter

Contributed Article: Design, Synthesis, and Biological Evaluation of Betulinic Acid Derivatives as New Antitumor Agents for Leukemia

Testimonial by Surovi Saikia!

Surovi Saikia

Contributed Article: Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anti-Cancer Potential of Aroma Compounds of Plant Essential Oils

Podcast: Synthesis of novel imine stilbene analogues exhibiting potent anticancer activity

Author(s): Raju Naini, Ravikumar Eslavath , Singh S Surya, Rama Krishna Kancha, Venkateswara Rao Khareedu, Dashavantha Reddy Vudem

For article details, visit: http://www.eurekaselect.com/151119

Subscribe our YouTube channelhttp://bit.ly/1lr0czy

Testimonial by Surovi Saikia!

Surovi Saikia

Contributed Article: Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anti-Cancer Potential of Aroma Compounds of Plant Essential Oils

Testimonial by Dr. Yizhe Cheng!

Imprimir

Contributed Article: Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors

Editor’s Choice – “Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1″

Journal: Anti-Cancer Agents in Medicinal Chemistry

Author(s): Adisorn Ratanaphan, Tidarat Nhukeaw, Khwanjira Hongthong and Paul J Dyson

 

acamc

Abstract

Background: The RAPTA-EA1 complex [ruthenium(II)-arene 1,3,5-triaza-7-phosphaadamantane (pta) complex with an arene-tethered ethacrynic acid ligand] has been reported to overcome drug resistance that developed due to the current use of platinum-based treatments. However, the exact mechanism of action of RAPTA-EA1 remains largely unexplored and unknown.

Objective: Here we have further studied the effect of RAPTA-EA1 on BRCA1-defective HCC1937 breast cancer cells and compared its effects on BRCA1-competent MCF-7 breast cancer cells.

Method: HCC1937 and MCF-7 breast cancer cells were treated with the RAPTA-EA1 complex. The cytotoxicity of ruthenium-induced cells was evaluated by a MTT assay. Cellular uptake of ruthenium was determined by ICP-MS. Cell cycle and apoptosis were assessed using a flow cytometer. Expression of BRCA1 mRNA and its encoded protein was quantitated by a real-time RT-PCR and Western blotting.

Results: Differences in cytotoxicity were correlated with the differential accumulations of ruthenium and the induction of apoptosis. The ruthenium complex caused dramatically more damage to the BRCA1 gene in the BRCA1-defective HCC1937 cells than to the BRCA1-competent MCF-7 cells. It decreased the expression of BRCA1 mRNA in the BRCA1-competent cells, while in contrast, its expression increased in the BRCA1-defective cells. However, the expression of the BRCA1 protein was significantly reduced in both types of breast cancer cells.

Conclusion: The results presented here have demonstrated a differential cellular response for the BRCA1-defective and BRCA1-competent breast cancer cells to RAPTA-EA1. These findings have provided more insight into the actions and development of the ruthenium-based compounds for use for the treatment of breast cancer.

Read more here: http://benthamscience.com/journals/anti-cancer-agents-in-medicinal-chemistry/volume/17/issue/2/page/212/

Upcoming Thematic Issue – Cold Atmospheric Plasma Activated Solution: A new Approach for Cancer Treatment

acamc-pankaj-attri

http://benthamscience.com/journals/anti-cancer-agents-in-medicinal-chemistry/

New Issue :: Anti-Cancer Agents in Medicinal Chemistry 17, Issue 1

Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents.

Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication.

Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.

acamc

 

Articles from the journal Anti-Cancer Agents in Medicinal Chemistry 17, Issue 1:

               For details on the articles, please visit this link :: http://bit.ly/2j3x3RU

New Issue :: Anti-Cancer Agents in Medicinal Chemistry 16, Issue 12

Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents.

Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication.

Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.

85c3788846bd8ec1ea15ac3238253a3704027f5ba597238ad9pimgpsh_fullsize_distr

Articles from the journal Anti-Cancer Agents in Medicinal Chemistry 16, Issue 12:                    

 

For details on the articles, please visit this link :: http://bit.ly/2fmVKaq     

p                                     

Highlighted Article Flyer for the journal “Anti-Cancer Agents in Medicinal Chemistry”

acamc-articles_16-12-vivek-asati

http://benthamscience.com/journals/anti-cancer-agents-in-medicinal-chemistry/